This analysis revealed that pre-treatment HbA1C, fasting blood glucose, random blood glucose, and urine glucose were significantly higher in the responsive group (Table 3, Fig
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss
Ahrn B
Methods: To investigate the causal relationship of GLP-1RAs with PI, we conducted a 2-sample mendelian randomization (MR) study based on summary statistics from genome-wide association studies (GWAS)
Z68.30 BMI 30.0-30.9, adult Z68.31 BMI 31.0-31.9, adult Z68.32 BMI 32.0-32.9, adult Z68.33 BMI 33.0-33.9, adult Z68.34 BMI 34.0-34.9, adult Z68.35 BMI 35.0-35.9, adult Z68.36 BMI 36.0-36.9, adult Z68.37 BMI 37.0-37.9, adult Z68.38 BMI 38.0-38.9, adult Z68.39 BMI 39.0-39.9, adult Z68.41 BMI 40.0-44.9, adult Z68.42 BMI 45.0-49.9, adult Z68.43 BMI 50.0-59.9, adult Z68.44 BMI 60.0-69.9, adult Z68.45 BMI 70 or greater, adult Note: For pediatric patients aged 2-19 years, BMI percentiles are used: Z68.51 BMI less than 5th percentile for age Z68.52 BMI 5th percentile to less than 85th percentile for age Z68.53 BMI 85th percentile to less than 95th percentile for age Z68.54 BMI greater than or equal to 95th percentile for age 3
